Cancer Research Meeting Calendar  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 11111, December 1, 2007. doi: 10.1158/0008-5472.CAN-07-2858
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weidhaas, J. B.
Right arrow Articles by Slack, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weidhaas, J. B.
Right arrow Articles by Slack, F. J.

Priority Reports

MicroRNAs as Potential Agents to Alter Resistance to Cytotoxic Anticancer Therapy

Joanne B. Weidhaas1, Imran Babar2, Sunitha M. Nallur1, Phong Trang1, Sarah Roush2, Michelle Boehm2, Erin Gillespie1 and Frank J. Slack2

1 Department of Therapeutic Radiology, Yale University School of Medicine; and 2 Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut

Requests for reprints: Joanne B. Weidhaas, Department of Therapeutic Radiology, Yale University School of Medicine, 333 Cedar Street, P. O. Box 208040, New Haven, CT 06520. Phone: 203-737-4267; Fax: 203-785-6309; E-mail: joanne.weidhaas{at}yale.edu or Frank J. Slack, Department of Molecular, Cellular and Developmental Biology, Yale University, P.O. Box 208103, New Haven, CT 06520. E-mail: frank.slack{at}yale.edu.

Tumor cells use preexisting prosurvival signaling pathways to evade the damaging and cytotoxic effects of anticancer agents. Radiation therapy is a primary form of cytotoxic anticancer treatment, but agents that successfully modify the radiation response in vivo are lacking. MicroRNAs (miRNA) are global gene regulators that play critical roles in oncogenesis and have been found to regulate prosurvival pathways. However, there is little understanding of how cellular miRNA expression affects the response of a cancer to cytotoxic therapy and ultimately outcome. The let-7 family of miRNAs regulates expression of oncogenes, such as RAS, and is specifically down-regulated in many cancer subtypes. In fact, low levels of let-7 predict a poor outcome in lung cancer. Here, we report that the let-7 family of miRNAs is overrepresented in a class of miRNAs exhibiting altered expression in response to radiation. More strikingly, we also can create a radiosensitive state when the select let-7 family of miRNAs is overexpressed in vitro in lung cancer cells and in vivo in a Caenorhabditis elegans model of radiation-induced cell death, whereas decreasing their levels causes radioresistance. In C. elegans, we show that this is partly through control of the proto-oncogene homologue let-60/RAS and genes in the DNA damage response pathway. These findings are the first direct evidence that miRNAs can suppress resistance to anticancer cytotoxic therapy, a common feature of cancer cells, and suggest that miRNAs may be a viable tool to augment current cancer therapies. [Cancer Res 2007;67(23):11111–6]




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
K. K.W. To, R. W. Robey, T. Knutsen, Z. Zhan, T. Ried, and S. E. Bates
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2
Mol. Cancer Ther., October 1, 2009; 8(10): 2959 - 2968.
[Abstract] [Full Text] [PDF]


Home page
RNAHome page
G. Sotiropoulou, G. Pampalakis, E. Lianidou, and Z. Mourelatos
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell
RNA, August 1, 2009; 15(8): 1443 - 1461.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Seike, A. Goto, T. Okano, E. D. Bowman, A. J. Schetter, I. Horikawa, E. A. Mathe, J. Jen, P. Yang, H. Sugimura, et al.
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
PNAS, July 21, 2009; 106(29): 12085 - 12090.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Yang, S. Kaur, S. Volinia, J. Greshock, H. Lassus, K. Hasegawa, S. Liang, A. Leminen, S. Deng, L. Smith, et al.
MicroRNA Microarray Identifies Let-7i as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer
Cancer Res., December 15, 2008; 68(24): 10307 - 10314.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. M. Nelson and G. J. Weiss
MicroRNAs and cancer: past, present, and potential future
Mol. Cancer Ther., December 1, 2008; 7(12): 3655 - 3660.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. W. Nasser, J. Datta, G. Nuovo, H. Kutay, T. Motiwala, S. Majumder, B. Wang, S. Suster, S. T. Jacob, and K. Ghoshal
Down-regulation of Micro-RNA-1 (miR-1) in Lung Cancer: SUPPRESSION OF TUMORIGENIC PROPERTY OF LUNG CANCER CELLS AND THEIR SENSITIZATION TO DOXORUBICIN-INDUCED APOPTOSIS BY miR-1
J. Biol. Chem., November 28, 2008; 283(48): 33394 - 33405.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.